1. Favipiravir biotransformation in liver cytosol: Species and sex differences in humans, monkeys, rats, and mice
- Author
-
Toshiko Tanaka-Kagawa, Hideto Jinno, Keita Saito, Takashi Isobe, Susumu Ohkawara, and Nobumitsu Hanioka
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,Metabolite ,Pharmaceutical Science ,Oxidative phosphorylation ,Favipiravir ,Biology ,Antiviral Agents ,030226 pharmacology & pharmacy ,Rats, Sprague-Dawley ,Mice ,Young Adult ,03 medical and health sciences ,chemistry.chemical_compound ,Cytosol ,0302 clinical medicine ,Species Specificity ,Biotransformation ,Internal medicine ,medicine ,Animals ,Humans ,Pharmacology (medical) ,Child ,Aldehyde oxidase ,Aged ,Sex differences in humans ,Pharmacology ,Sex Characteristics ,General Medicine ,Middle Aged ,Amides ,Macaca fascicularis ,Endocrinology ,Liver ,chemistry ,Child, Preschool ,Pyrazines ,030220 oncology & carcinogenesis ,Microsomes, Liver ,Female ,Drug metabolism - Abstract
Favipiravir is an antiviral agent effective against several RNA viruses that is converted into an inactive oxidative metabolite (M1), mainly by aldehyde oxidase, in humans. In the present study, the biotransformation of favipiravir into M1 in male and female humans, monkeys, rats, and mice was examined in an in vitro system using liver cytosolic fractions. The kinetics for M1 formation followed the Michaelis-Menten model in all species. The Km , Vmax , and CLint values in humans were 602 µM, 466 pmol/min/mg protein, and 776 nl/min/mg protein in males, respectively, and 713 µM, 404 pmol/min/mg protein, and 567 nl/min/mg protein in females, respectively. Species differences in CLint values were monkeys > humans > mice > rats in both males and females, and the variations for males and females were 120- and 96-fold, respectively. Sex differences in CLint values were males > females in humans and mice, females > males in monkeys and rats, and marked variation (4.3-fold) was noted in mice. This suggests that the roles of aldehyde oxidase in the hepatic metabolism of favipiravir differ extensively depending on the species and sex, and this study will aid in the assessment of the antiviral activities of favipiravir against novel and/or variant viruses.
- Published
- 2021
- Full Text
- View/download PDF